Menu

Former WHO Director-General Dies

Halfdan Mahler, the third leader of the World Health Organization, has passed away at age 93.

Dec 16, 2016
Tracy Vence

WIKIMEDIA, ERLINGMANDELMANN

Halfdan Mahler, the third Director-General of the World Health Organization (WHO), died this week (December 14). He was 93.

Mahler joined the agency in 1951. During his tenure at WHO, he worked with the National Tuberculosis Programme in India and led the tuberculosis unit at WHO headquarters, in Geneva. Mahler was also Director Project Systems Analysis and Assistant Director-General, before becoming Director-General in 1973. He held that role until his retirement, in 1988.

Mahler then directed the International Planned Parenthood Federation until 1995. “He will be deeply missed by the global health community,” the WHO said in a statement.

 

 

 

Thumbnail image: WHO

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.